Andrei Vladislavovich Pavlysh

Andrei Vladislavovich Pavlysh

Auto-generated profile, based on publicly available information

Andrei Vladislavovich Pavlysh

North-Western State Medical University Named After I.I. Mechnikov

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Verified
Journal Article
Open access
PDF file
АКА. С. Колбин
А. С. Колбин
IVI A Vilyum
I A Vilyum
MPM A Proskurin
M A Proskurin
YBYu E Balikina
Yu E Balikina
АПА. В. Павлыш
А. В. Павлыш
ЮБЮ. Е. Балыкина
Ю. Е. Балыкина
Objective.To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the Russian healthcare system.Materials and methods.A decision analysis model was used followed by Markov modelling for the economic evaluation of the drugs in the treatment of metastatic TNBC. We used the «cost-effectiveness» analysis and the «impact on the budget» (BIA) analysis. Two therapeutic approaches were evaluated: the use of combined therapy with atezolizumab + nab-paclitaxel and monotherapy with nab-paclitaxel. The analysis included direct costs. Additionally, the obtained pharmacoeconomical indicators of the use of a combination of atezolizumab and nab-paclitaxel and other drugs for the treatment of locally advanced and metastatic breast cancer were compared.Results. The use of the estimated therapeutic approaches in the treatment of metastatic TNBC was characterized by the following costs: with a modelling horizon of 1 year, the cost of using atezolizumab in combination with nab-paclitaxel was 5,076,321 rubles per patient. The costs for the use of single agent nab-paclitaxel with was 60 % less than: — 2 020 038,78 RUB. At the same time, the effectiveness of therapy with a combination of atezolizumab and nab-paclitaxel clinically significantly exceeded that of nab-paclitaxel monotherapy: a 38 % reduction in the risk of death or progression, a 10-fold increase in the frequency of complete response to therapy (10 vs 1 %), and a 7-month increase in the median overall survival (25 vs 18 months). The economic evaluation of the combination of atezolizumab with nab-paclitaxel was carried out with the calculation of the incremental cost-effectiveness ratios (ICER) — the calculation of the additional cost for each additional year of life in comparison with standard therapy. Due to the fact that currently in Russia for patients with metastatic TNBC no similar performance modes of therapy ICER for the combination atezolizumab + nab-paclitaxel compared with the ICER for palbociclib in combination with fulvestrant (drugs, showed improved overall survival in clinical research and included in clinical guidelines for the treatment of diseases of the same class ICD-10 in locally advanced and metastatic breast cancer). The ICER for overall survival at the end of the first year of follow-up for atezolizumab + nab-paclitaxel and palbociclib + fulvestrant was 30.5 million rubles and 47.4 million rubles, respectively. For the combination of atezolizumab + nab-paclitaxel, ICER is lower than the similar ICER for the palbociclib + fulvestrant mode by 36 %. Analysis of trends in the weighted average cost of systemic pathogenetic treatment of breast cancer (breast cancer) shows the following: increased use of the combination of atezolizumab + nab-paclitaxel for the treatment of patients with metastatic TNBC doesn’t lead to a considerable growth in the cost of therapy in patients with breast cancer — providing therapy to 1400 patients that includes the entire target population of patients with TNBC and expression of PD-L1 in Russia changes in the costs of chemotherapy and immunotherapy of breast cancer will remain within 2.6 %.Conclusion. Pharmacoeconomic indicators of the use of atezolizumab in combination with nab-paclitaxel are more cost-effective in comparison with other expensive schemes for the treatment of breast cancer, and tumors of other localities that are actively used in current practice, which suggests the acceptability and feasibility of introducing and expanding the use of this therapeutic option in the target population.

22 July 2024 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Open access
OVOlesya Vasilyeva
Olesya Vasilyeva
DKDmitrii Al. Kachanov
Dmitrii Al. Kachanov
ASAlexander Nikolaevich Stukov
Alexander Nikolaevich Stukov
GTGrigory Viktorovich Tochilnikov
Grigory Viktorovich Tochilnikov
APAndrey Vladislavovich Pavlysh
Andrey Vladislavovich Pavlysh
БМБеляев Алексей Михайлович
Беляев Алексей Михайлович
Currently, the targeted delivery of anticancer drugs can significantly increase the effectiveness of therapy, reduce the side effects of systemic chemotherapy, and improve the quality of patients with cancer. This review aimed to summarize data about the domestic antitumor drug 2,4-bis(1-aziridinyl)-6-(2,2-dimethyl-5-hydroxymethyl-1,3-dioxan-5-yl)amino-1,3,5-thriazine (dioxadet), its nanoforms, possibilities of its use in the clinic, and main antitumor nanodrugs clinically introduced in recent years. Library databases (eLibrary, PubMed, CyberLeninka, ResearchGate, Springer, Wiley Online Library, and Elsevier) were searched for relevant information. The literature review summarizes data on the preclinical trials of dioxadet and provides information on its nanoforms, such as nanogels, nanodiamonds, silica particles, and copolymers with lactic and caproic acids. New drug nanoforms open up opportunities to reduce drug side effects and systemic toxicity, maintain optimal therapeutic concentrations, increase the drug circulation time in the blood, and control its release. The possibility of using chemopreparation cytotoxic doses is the main advantage of new nanodrugs. To date, approximately 20 antitumor nanodrugs have been introduced in clinical practice, and some nanodrugs are undergoing preclinical trials or are in various phases of clinical trials. Thus, the development of a new effective nanoform, i.e., dioxadet, makes it possible to ensure targeted drug delivery in higher cytotoxic doses to target cells, increase selective action, and reduce cytostatic toxicity to normal cells.

13 May 2020 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
KLKirill E. Levikin
Kirill E. Levikin
DKDmitrii A. Kachanov
Dmitrii A. Kachanov
GLGalina Ya. Lapkina
Galina Ya. Lapkina
ASAlexander A. Slobozhanin
Alexander A. Slobozhanin
APAndrei V. Pavlysh
Andrei V. Pavlysh
The depressive disorders remain one of the global problems of modern society. Many issues related to this topic remain open for discussion. It is reliably known that tropical fish Danio rerio (zebrafish) are the most studied and practical model methods of preclinical studies. They have several advantages over other laboratory animals. Danio Rerio is great for modeling stress and depression in order to identify the manifestations of medication to identify the manifestations of this condition. Methods. Danio Rerio when exposed to non-selective antidepressants and related serotonin reuptake inhibitors. Danio Rerio is under stress and depression due to acute exposure to caffeine and the subsequent use of antidepressants with timely recording and processing of the results. Results. The effect of sertraline on the Danio rerio group in order to identify the state of stress and depression was more effective in comparison with the results obtained using amitriptyline as an antidepressant. Conclusions. Sertraline in therapeutic concentration has a greater rate of elimination from anxiety and depression, which in turn allows us to argue about its greater effectiveness. In medical practice, it is better to prescribe drugs of the group of selective serotonin reuptake inhibitors in order to achieve a faster effect.

27 April 2024 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
APAndrei Vladislavovich Pavlysh
Andrei Vladislavovich Pavlysh
TGTatiana Yurievna Galunova
Tatiana Yurievna Galunova
DKDmitrii Al. Kachanov
Dmitrii Al. Kachanov
GLGalina Ya. Lapkina
Galina Ya. Lapkina
The use of antibiotics in the treatment of various diseases dramatically changes the quantitative and qualitative compositions of both pathogenic and symbiotic microbiota. Oral and parenteral use of antibacterial drugs affects and changes the quantitative and qualitative compositions of the intestinal microbiota, which subsequently entails changes in the cell development and long-term violations of physiology at all levels of functioning of the macroorganism. This study analyzed available data on modern probiotic drugs, which help improve the normal microbiota in the human body. The results revealed the undoubted effectiveness of various probiotics in acute and antibiotic-associated diarrhea and eradication of Helicobacter pylori.

20 June 2025 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
APA.V. Pavlysh
A.V. Pavlysh
ABA.L. Bakulev
A.L. Bakulev
Objective. To evaluate the economic feasibility of expanding the use of netakimab for the treatment of adult patients with moderate to severe psoriasis vulgaris compared to other biologics and small molecules used in the health care settings of the Russian Federation. Material and methods. Costs were calculated according to the dosing regimen approved in the Russian Federation for all considered treatment options for adults with moderate to severe psoriasis vulgaris. The analysis used the registered prices inlcuding VAT of the manufacturer, including value-added tax. If generics or biosimilars were available, the calculation was based on the minimum registered prices. Results. Netakimab is the least costly in treating psoriasis vulgaris compared to other biologics and small molecules with comparable or superior efficacy assessed using PASI 75 and PASI 90. To achieve costs equal to those required for the treatment of psoriasis vulgaris with netakimab for 2 years, it is necessary to reduce the cost of competitors by 30—74%, which corresponds to the provision of 0.4 to 2.8 additional packages free of charge for each package purchased. Conclusion. Expanding the use of netakimab for treating adult patients with moderate to severe psoriasis vulgaris will reduce the cost of the Russian health care system, with comparable or higher clinical efficacy compared to other genetically engineered biological drugs and small molecules. Netakimab can be considered the drug of choice.

27 March 2023 in Psychopharmacology and Addiction Biology
Verified
Journal Article
Open access
PDF file
TSTatiana A. Sergeeva
Tatiana A. Sergeeva
DKDmitriy A. Kachanov
Dmitriy A. Kachanov
EBEvgeniya A. Belogurova
Evgeniya A. Belogurova
ABAnfisa B. Batalova
Anfisa B. Batalova
APAndrei V. Pavlysh
Andrei V. Pavlysh
Fibrotic changes in lung tissues after coronavirus disease 2019 (COVID-19) are receiving increasing attention. Current tasks for the medical community include not only minimizing the effects on etiotropic factors and increasing the bodys resistance to the damaging effects of viruses but also minimizing the number of complications and in the long term reducing morbidity and improving the prognosis and quality of life of patients after a severe viral infection. The aim of this study was to describe a clinical case of the effectiveness of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19. A 46-year-old patient was diagnosed with COVID-19, which manifested as an acute respiratory viral infection in the clinic. She was hospitalized in a specialized department. Computed tomography noted 80% of lung damage, and oxygen saturation decreased to 70%. She was treated with antibiotics, antiviral drugs, anticoagulants, and hormones. After 1 month, she was discharged with improvement, and residual effects of lung damage (56%). In the post-hospital period, bovhyaluronidase azoximer for 25 days was prescribed. Clinical, radiological, laboratory, and clinical applied in a hospital. On computed tomography, no signs of infiltrative changes in the lungs and signs of pneumofibrosis, a picture of viral pneumonia, were noted. The case highlights the positive action of bovhyaluronidase azoxymer as an immunomodulatory and antifibrosing agent.